U.S. Markets closed

Krystal Biotech, Inc. (KRYS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
67.93+5.39 (+8.62%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close65.67
Open65.12
Bid62.93 x 1200
Ask63.43 x 4000
Day's Range62.38 - 66.10
52 Week Range37.68 - 87.29
Volume148,971
Avg. Volume163,210
Market Cap1.508B
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory
    Investor's Business Daily

    Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory

    KrystalBiotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

  • Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
    Simply Wall St.

    Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • Benzinga

    Krystal Biotech Prices Upsized $125 Million Capital Offering at $65/Share

    Krystal Biotech Inc (NASDAQ: KRYS) has priced the previously announced underwritten public offering of 1.923 million common shares at $65/share, representing gross proceeds of $125 million. Underwriters having an option to purchase up to an additional 288 thousand shares. Net proceeds from this offering together with its existing cash, cash equivalents, and short-term investments will be used to complete the ongoing pivotal trial of B-VEC for DEB and prepare for potential commercialization, advance the development of KB105 in TGM1-deficient ichthyosis, preclinical development of KB104 for Netherton syndrome, advance development of KB407 for cystic fibrosis, accelerate the Company's emerging respiratory pipeline, as well as for working capital and general corporate purposes. The offering is expected to close by February 5. KRYS shares are down 5.48% at $67.04 in the pre-market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaAmgen Shares Dip On Light 2021 Outlook, Paused StudiesEli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.